Halozyme Therapeutics Inc (HALO)

[maumar]

Last post. I just skimmed through the very long transcript. There may be more interesting bits relating to Halo.

Operator

Next question come is from Philippe Lanone from Natixis. Please go ahead.

Philippe Lanone

So, gentlemen, thank you for taking my questions. Quick one on the impact of biosimilars on MabThera in Europe. You mentioned the preference for subcu. But could you just specifically say whether the minus 16% is only on the IV form or vastly or the vast majority of it on the IV form or is the subcu from is also impacted, as far as you see it, I mean in terms of your sales declining?

Daniel O’Day

Good. So, just quickly on the biosimilar, happy to give you a little bit more color. That minus 16% in the quarter, two-thirds of it, we believe is due to biosimilar erosion. And of that biosimilar erosion, it’s about 50% price and 50% volume. That gives you a little bit more color. The other third of the 16% is what I would call kind of a normal price decreases that you see across Europe. I think we had a slight decline in Poland and in France for instance, in the third quarter. So, I hope that gives you a little bit of a sense for it.

So far the subcutaneous I think has been holding up quite well. And in many cases, the IV and subcutaneous tenders have been so far separate in some of the markets as well. So that’s as much color as I can give you to-date. And obviously as we have more experience in the coming quarters, I’ll do my best to give you a little bit more information on that. And Roland...